BACKGROUND: Progression of parkinsonian motor impairment is usually rapid and relentless in multiple system atrophy (MSA). However, it may also be subject to considerable variation. Prospective natural history studies using validated rating scales are required to accurately determine the progression of parkinsonism in MSA. OBJECTIVE: To assess the progression of parkinsonism in patients with the Parkinson variant of MSA. METHODS: Parkinsonian motor impairment was assessed on regular therapy at two time points (mean follow-up 11.8 months, SD 1.4) using the Hoehn and Yahr scale (H&Y), the Schwab and England ADL scale (SES) and the motor examination section of the UPDRS (UPDRS-III) in 38 patients with clinically probable MSA-P. RESULTS: We examined 38 patients with probable MSA-P (mean age 63.2 years, SD 7.4; mean disease duration 4.1 years, SD 3.0). The mean difference of UPDRS-III between baseline and follow-up was 10.8 (95% CI 8.6-12.9), consistent with an average annual 28.3 % increase of UPDRS-III baseline scores. Several variables were associated with faster progression of parkinsonism including low baseline global motor disability as assessed by H&Y and SES, low baseline UPDRS-III score, and short disease duration. UPDRS-III progression was unrelated to gender, age at symptom onset, and age at baseline visit. CONCLUSION: This is the first observational study on UPDRS rates of decline in MSA. The observed 28.6% annual increase of UPDRS-III scores illustrates the rapid progression of motor impairment in MSA. Furthermore, motor progression appeared to be accelerated during the early disease stages. Our data allow sample size calculations that may be helpful for the planning of future therapeutic trials.
BACKGROUND: Progression of parkinsonian motor impairment is usually rapid and relentless in multiple system atrophy (MSA). However, it may also be subject to considerable variation. Prospective natural history studies using validated rating scales are required to accurately determine the progression of parkinsonism in MSA. OBJECTIVE: To assess the progression of parkinsonism in patients with the Parkinson variant of MSA. METHODS:Parkinsonian motor impairment was assessed on regular therapy at two time points (mean follow-up 11.8 months, SD 1.4) using the Hoehn and Yahr scale (H&Y), the Schwab and England ADL scale (SES) and the motor examination section of the UPDRS (UPDRS-III) in 38 patients with clinically probable MSA-P. RESULTS: We examined 38 patients with probable MSA-P (mean age 63.2 years, SD 7.4; mean disease duration 4.1 years, SD 3.0). The mean difference of UPDRS-III between baseline and follow-up was 10.8 (95% CI 8.6-12.9), consistent with an average annual 28.3 % increase of UPDRS-III baseline scores. Several variables were associated with faster progression of parkinsonism including low baseline global motor disability as assessed by H&Y and SES, low baseline UPDRS-III score, and short disease duration. UPDRS-III progression was unrelated to gender, age at symptom onset, and age at baseline visit. CONCLUSION: This is the first observational study on UPDRS rates of decline in MSA. The observed 28.6% annual increase of UPDRS-III scores illustrates the rapid progression of motor impairment in MSA. Furthermore, motor progression appeared to be accelerated during the early disease stages. Our data allow sample size calculations that may be helpful for the planning of future therapeutic trials.
Authors: I Litvan; C G Goetz; J Jankovic; G K Wenning; V Booth; J J Bartko; A McKee; K Jellinger; E C Lai; J P Brandel; M Verny; K R Chaudhuri; R K Pearce; Y Agid Journal: Arch Neurol Date: 1997-08
Authors: François Tison; Farid Yekhlef; Virginie Chrysostome; Eric Balestre; Niall P Quinn; Werner Poewe; Gregor K Wenning Journal: Mov Disord Date: 2002-07 Impact factor: 10.338
Authors: C W Olanow; R A Hauser; L Gauger; T Malapira; W Koller; J Hubble; K Bushenbark; D Lilienfeld; J Esterlitz Journal: Ann Neurol Date: 1995-11 Impact factor: 10.422
Authors: Christian Brenneis; Karl Egger; Christoph Scherfler; Klaus Seppi; Michael Schocke; Werner Poewe; Gregor K Wenning Journal: J Neurol Date: 2007-02 Impact factor: 4.849
Authors: K L Poston; C C Tang; T Eckert; V Dhawan; S Frucht; J-P Vonsattel; S Fahn; D Eidelberg Journal: Neurology Date: 2012-04-04 Impact factor: 9.910
Authors: Soyoung Jin; Minyoung Oh; Seung Jun Oh; Jungsu S Oh; Sang Ju Lee; Sun Ju Chung; Chong Sik Lee; Jae Seung Kim Journal: Nucl Med Mol Imaging Date: 2012-11-03
Authors: S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet Journal: Neurology Date: 2008-08-26 Impact factor: 9.910
Authors: Christine A M Payan; François Viallet; Bernhard G Landwehrmeyer; Anne-Marie Bonnet; Michel Borg; Franck Durif; Lucette Lacomblez; Frédéric Bloch; Marc Verny; Jacques Fermanian; Yves Agid; Albert C Ludolph; Peter N Leigh; Gilbert Bensimon Journal: PLoS One Date: 2011-08-04 Impact factor: 3.240
Authors: Gregor K Wenning; Felix Geser; Florian Krismer; Klaus Seppi; Susanne Duerr; Sylvia Boesch; Martin Köllensperger; Georg Goebel; Karl P Pfeiffer; Paolo Barone; Maria Teresa Pellecchia; Niall P Quinn; Vasiliki Koukouni; Clare J Fowler; Anette Schrag; Christopher J Mathias; Nir Giladi; Tanya Gurevich; Erik Dupont; Karen Ostergaard; Christer F Nilsson; Håkan Widner; Wolfgang Oertel; Karla Maria Eggert; Alberto Albanese; Francesca del Sorbo; Eduardo Tolosa; Adriana Cardozo; Günther Deuschl; Helge Hellriegel; Thomas Klockgether; Richard Dodel; Cristina Sampaio; Miguel Coelho; Ruth Djaldetti; Eldad Melamed; Thomas Gasser; Christoph Kamm; Giuseppe Meco; Carlo Colosimo; Olivier Rascol; Wassilios G Meissner; François Tison; Werner Poewe Journal: Lancet Neurol Date: 2013-02-05 Impact factor: 44.182